Atom Therapeutics Co.

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Atom Therapeutics Co. sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 3 currently recruiting 5 completed early-phase tilt top decile by trial count

Atom Therapeutics Co.: 9 sponsored US clinical trials, 3 recruiting.

Atom Therapeutics Co. sponsors 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Gout Flare, with 1 trials.

Top-decile sponsor footprint

Atom Therapeutics Co. ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 2

Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis

NCT07303777
RECRUITING Phase 1

Drug-Drug Interaction Study of ABP-671 in Gout Patients

NCT07367971
RECRUITING Phase 2

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

NCT07145229
TERMINATED Phase 2

Extension Study of ABP-671 in Participants With Gout

NCT06276556
COMPLETED Phase 1

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers

NCT06258213
COMPLETED Phase 2

Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

NCT05818085
COMPLETED Phase 1

Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects

NCT04303039
COMPLETED Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671

NCT04060173
COMPLETED Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects

NCT03906006

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 4

Therapeutic Areas

Acute Gout Flare 1
Gout Flares 1
Gout Flare 1
Acute Gouty Arthritis 1

What is open in the Atom Therapeutics Co. pipeline

3 recruiting of 9 indexed (33% open); 5 completed (56%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Acute Gout Flare (1 trial), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Atom Therapeutics Co.: open-pipeline peers nationwide

Peers matched on 9 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

Atom Therapeutics Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%10%20%30%40%50% Total trials Recruiting share Atom Therapeutics Co.4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyAaron CookAbivax S.A.Actuated MedicalAdagio Medical
Atom Therapeutics Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Atom Therapeutics Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Atom Therapeutics Co. page

9 registered trials is a research-attention snapshot, not an endorsement of Atom Therapeutics Co. or any single study.

  • 3 of Atom Therapeutics Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Acute Gout Flare is the condition Atom Therapeutics Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Gout Flare trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Atom Therapeutics Co. pipeline card: 9 registered trials from official public datasets.Report a data error.